Primo Biotech announced today a significant advancement in the development of PB-012, its proprietary radiotracer focusing on angiogenesis. The company has successfully completed the First Patient In (FPI) for the Phase I clinical trial at a medical center in Kaohsiung. This clinical trial aims to evaluate the diagnostic efficacy and safety of PB-012 in patients…
According to Taiwan’s National Health Insurance data, 9,858 new cases of prostate cancer and 1,897 related deaths were recorded in 2024, making it the third most common cancer among men and the fastest-growing malignancy in recent years. Prof. Yen-Chuan Ou, Superintendent of the Research and Innovation Center at Tung’s Taichung MetroHarbor Hospital, emphasized that the…
Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a prominent biotech firm specializing in novel drug development. The two companies will jointly develop and manufacture an innovative peptide-based radioligand therapeutic, targeting solid tumors diagnosis and treatment —…
Primo Biotechnology Co., Ltd., a pioneering developer of radiopharmaceuticals, today announced a strategic partnership with Terthera B.V., a radionuclide production-focused company based in The Netherlands. Under the agreement, Terthera will supply Primo with high-purity, non-carrier-added (NCA), GMP-grade Terbium-161 (Tb-161), a next-generation therapeutic radionuclide. Primo has also secured exclusive distribution rights for Tb-161 in Taiwan. This…
Primo Biotechnology Co., Ltd., a pioneering radiopharmaceutical company in Taiwan, announced the successful completion of its NT$220 million Series A funding round. With total capital raised now exceeding NT$500 million, including seed and early-stage investments, Primo is accelerating its path toward leadership in radioligand theranostics. The company also revealed plans to launch its IPO in…
Taipei, Taiwan – Primo Biotechnology Co., Ltd. (“Primo”) proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Drug Administration (TFDA) and has been award dual certification for PIC/S GMP and GDP. This achievement demonstrates Primo’s dedication to meeting international quality standards for nuclear medicine production and sets the stage…
Taipei, Taiwan, March 19, 2025 – In response to the growing burden of prostate cancer in Taiwan, Primo Biotechnology Co., Ltd. (“Primo”) has formed a strategic partnership with Germany-based ABX advanced biochemical compounds GmbH (ABX) to lay the groundwork for introducing PB01 to the Taiwanese market. Data from Taiwan Cancer Registry indicate a steady increase…
Partnership Delivers Advanced Radioligand Treatments Across Asia-Pacific, Expanding Access to Cutting-Edge Cancer Therapies Taipei, Taiwan – Primo Biotechnology (“Primo”) today announced a strategic partnership with SHINE Technologies, LLC, (“SHINE”) a global leader in nuclear medicine production. The partnership includes a supply and exclusive distribution agreement to introduce Ilumira (n.c.a. lutetium-177, Lu-177), SHINE’s high-purity therapeutic isotope,…
Taipei, Taiwan – Primo Biotechnology Co., Ltd., a leader in precision medicine and radioligand theranostics (RLT), is proud to announce its collaboration with Antelope Surgical Solutions, Inc., a pioneering biotechnology company based in New York, USA. This partnership will facilitate the world’s first FDA-approved Phase I/II clinical trial of AS1986NS, an innovative fluorescent imaging agent…
We are greatly honored to receive the award of Investment Paradigm from Taipei City Government. Thanks to the Project of Subsidies & Incentives For Taipei Industry, Primo Biotechnology is able to grow faster and take on difficult challenges. About Primo Biotechnology Primo Biotechnology is a pioneering leader in Asia’s nuclear medicine sector, dedicated to the…
